Insider Trading Alert - ENTA, FNSR And ISLE Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 15, 2015, 81 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $428.00 to $1,771,500.00.

Highlighted Stocks Traded by Insiders:

Enanta Pharmaceuticals (ENTA) - FREE Research Report

Or Yat Sun, who is Chief Scientific Officer at Enanta Pharmaceuticals, sold 3,750 shares at $42.47 on June 15, 2015. Following this transaction, the Chief Scientific Officer owned 215,731 shares meaning that the stake was reduced by 1.71% with the 3,750-share transaction.

The shares most recently traded at $43.01, up $0.54, or 1.25% since the insider transaction. Historical insider transactions for Enanta Pharmaceuticals go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 42,250
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 50,250
  • 24-Week # shares bought: 2,400
  • 24-Week # shares sold: 99,750

The average volume for Enanta Pharmaceuticals has been 308,500 shares per day over the past 30 days. Enanta Pharmaceuticals has a market cap of $783.4 million and is part of the health care sector and drugs industry. Shares are down 17.58% year-to-date as of the close of trading on Monday.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. The company has a P/E ratio of 6.9. Currently, there are 3 analysts who rate Enanta Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENTA - FREE

TheStreet Quant Ratings rates Enanta Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Enanta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Finisar (FNSR) - FREE Research Report

Young Joseph A, who is Exec. VP Global Operations at Finisar, sold 2,200 shares at $23.10 on June 15, 2015. Following this transaction, the Exec. VP Global Operations owned 200,042 shares meaning that the stake was reduced by 1.09% with the 2,200-share transaction.

The shares most recently traded at $22.51, down $0.59, or 2.62% since the insider transaction. Historical insider transactions for Finisar go as follows:

  • 4-Week # shares sold: 1,500
  • 12-Week # shares sold: 1,500
  • 24-Week # shares sold: 10,177

The average volume for Finisar has been 902,400 shares per day over the past 30 days. Finisar has a market cap of $2.4 billion and is part of the technology sector and computer hardware industry. Shares are up 17.41% year-to-date as of the close of trading on Monday.

Finisar Corporation provides optical subsystems and components for data communication and telecommunication applications in the United States, Malaysia, China, and internationally. The company has a P/E ratio of 73.5. Currently, there are 7 analysts who rate Finisar a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FNSR - FREE

TheStreet Quant Ratings rates Finisar as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full Finisar Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Isle of Capri Casinos (ISLE) - FREE Research Report

Mcdowell Virginia, who is President & CEO at Isle of Capri Casinos, sold 60,000 shares at $19.81 on June 15, 2015. Following this transaction, the President & CEO owned 850,065 shares meaning that the stake was reduced by 6.59% with the 60,000-share transaction.

The shares most recently traded at $20.71, up $0.90, or 4.33% since the insider transaction. Historical insider transactions for Isle of Capri Casinos go as follows:

  • 4-Week # shares sold: 5,870
  • 12-Week # shares sold: 5,870
  • 24-Week # shares sold: 5,870

The average volume for Isle of Capri Casinos has been 278,500 shares per day over the past 30 days. Isle of Capri Casinos has a market cap of $789.3 million and is part of the services sector and leisure industry. Shares are up 135.6% year-to-date as of the close of trading on Monday.

Isle of Capri Casinos, Inc., together with its subsidiaries, develops, owns, and operates regional gaming facilities and related dining, lodging, and entertainment facilities in the United States. The company has a P/E ratio of 25.9. Currently, there is 1 analyst who rates Isle of Capri Casinos a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ISLE - FREE

TheStreet Quant Ratings rates Isle of Capri Casinos as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Isle of Capri Casinos Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

What Angela Merkel's Uncertain Political Future Means for Greece's Debt Woes

What Angela Merkel's Uncertain Political Future Means for Greece's Debt Woes

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Goldman Is Bullish on Oil, Sees Demand Outweighing Inventory Concern

Goldman Is Bullish on Oil, Sees Demand Outweighing Inventory Concern